glp-1 obesity drugs updates today anti-obesity lead to substantial weight loss in the “real world” CMS Issues Coverage Guidance on

over-the-counter oral versions don't achieve the same systemic bioavailability because first-pass hepatic metabolism degrades methionine and glutathione before they reach therapeutic plasma levels

We may notice effects on skin color, immune response, and tissue repair, along with some potential risks that require attention

No masking symptoms while the underlying damage continues

Under the CV indication, patients with established cardiovascular disease and BMI 27+ qualify, and the 6-month lifestyle program is waived on most plans

However, current evidence has not shown that these medications directly interfere with blood clotting factors or standard hemophilia treatments